Chargement de la fiche…
Chargement de la fiche…
rhumatologie
Libéral
Saint-Pierre-de-Coutances (50200)
Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment · Lung Cancer Research Studies
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
2024–2025
Université du Québec à Montréal
2022–2024
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2014
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2012
Inserm
2012
Université Joseph Fourier
2012
Centre Hospitalier Universitaire de Grenoble
0
h-index
0
i10
0
citations
Le h-index mesure la productivité scientifique : ce médecin a publié 37 articles cités au moins 37fois par d'autres chercheurs. Plus c'est élevé, plus son travail influence la communauté médicale.
Côté patient
Comprendre votre pathologie, exercices à domicile, applications validées, paramédicaux à proximité — gratuit, sans inscription.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'Études Spécialisées
DE Docteur en médecine — Capacité / Certificat d'Études Spéciales
0
travaux
0
h-index
0
i10-index
0
citations
2026Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed ↗Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer
2025JTO clinical and research reports
PubMed ↗Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
2025Translational oncology
PubMed ↗MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
2024Lung cancer (Amsterdam, Netherlands)
PubMed ↗Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
2023Lung cancer (Amsterdam, Netherlands)
PubMed ↗VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
2022Journal for immunotherapy of cancer
PubMed ↗Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
2022International journal of cancer
PubMed ↗A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial
2022European journal of cancer (Oxford, England : 1990)
PubMed ↗Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
2022Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed ↗Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
2020Lung cancer (Amsterdam, Netherlands)
PubMed ↗Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
2020European journal of cancer (Oxford, England : 1990)
PubMed ↗Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
2020JTO clinical and research reports
PubMed ↗Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
2020Journal of clinical medicine
PubMed ↗Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
2020JTO clinical and research reports
PubMed ↗Development and Validation of a Simplified Prognostic Score in SCLC
2019European journal of cancer (Oxford, England : 1990)
PubMed ↗Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study
2019Cancers
PubMed ↗Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
2019Clinical lung cancer
PubMed ↗Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
2019Clinical lung cancer
PubMed ↗Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
2019British journal of cancer
PubMed ↗MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
2018Current osteoporosis reports
PubMed ↗Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy
2017Oncotarget
PubMed ↗Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
2017Oncotarget
PubMed ↗MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial
2017Bulletin du cancer
PubMed ↗[Clinical research activity of the French cancer cooperative network: Overview and perspectives]
2017ESMO open
PubMed ↗Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
2017The European respiratory journal
PubMed ↗Association between lung cancer somatic mutations and occupational exposure in never-smokers
2026Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
PubMed ↗Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial
2026Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed ↗Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
2022Lung cancer (Amsterdam, Netherlands)
PubMed ↗Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
2022The Lancet. Oncology
PubMed ↗Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
2021Lung cancer (Amsterdam, Netherlands)
PubMed ↗Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial
2021Clinical cancer research : an official journal of the American Association for Cancer Research
PubMed ↗First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
2020Clinical cancer research : an official journal of the American Association for Cancer Research
PubMed ↗Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial
2020The European respiratory journal
PubMed ↗First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
2020Rheumatology (Oxford, England)
PubMed ↗An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis
2019Clinical cancer research : an official journal of the American Association for Cancer Research
PubMed ↗Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
2019Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
PubMed ↗A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
2019The Lancet. Oncology
PubMed ↗Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
2018ESMO open
PubMed ↗Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
2026JTO clinical and research reports
PubMed ↗Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
2025Lung cancer (Amsterdam, Netherlands)
PubMed ↗Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
2025European journal of cancer (Oxford, England : 1990)
PubMed ↗Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
2025European journal of cancer (Oxford, England : 1990)
PubMed ↗Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"
2024Respiratory medicine and research
PubMed ↗Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
2023Lung cancer (Amsterdam, Netherlands)
PubMed ↗Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study
2018The European respiratory journal
PubMed ↗Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
2018The European respiratory journal
PubMed ↗Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times
2020Rheumatology (Oxford, England)
PubMed ↗An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis
2018Seminars in arthritis and rheumatism
PubMed ↗Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
2018The European respiratory journal
PubMed ↗Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times
2017Free radical biology & medicine
PubMed ↗Leflunomide prevents ROS-induced systemic fibrosis in mice
2020European journal of cancer (Oxford, England : 1990)
PubMed ↗Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial
2016Arthritis research & therapy
PubMed ↗Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study
2019Clinical cancer research : an official journal of the American Association for Cancer Research
PubMed ↗Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
2026Article
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
Journal of Clinical Oncology
2025Article
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
Translational Oncology
2025Article
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial
Clinical Cancer Research
2025Article
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
The Lancet Respiratory Medicine
2025Chapitre
Chapter 12 - Applications
2025Chapitre
Chapter 10. Specificities of PWR-SMRs
2025Article
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Lung Cancer
2024Congrès
IDNES a CEA projet dedicated to SMR concept for decarbonization beyond pure power generation
International Conference on Small Modular Reactors and their applications
Ouest-France
Déserts médicaux dans la Manche : le diagnostic d’un mal profond et des prescriptions qui marchent - Ouest-France
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPblkzRGJLR0ZZTkR5SUgtVFRvR2ptWkN1UEVieXBmTy1lVExQb1o2OEIzMkRjY1Z4UFh6eGxUbTBfckVKQW1UT2F5aEgzbkdBVEh2RE1TNTNzQ0VhRC10YzZBY2tfd3pUQU14dkM1bHVkZ2V0dkJxUXE1VmZqYjlHaUc2cGE5aVBvXzVZenRQR180cmlrWGZUYXF6S29HcUczWE1XYWNhdWZDdEhoOUl6NGFVdDBaYzVNQT
Ouest-France
« Rester ici, c’est un exploit » : dans la Manche, des assistants médicaux pour aider les praticiens - Ouest-France
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQOTBYVFRlcUJqeXpHS2d6eURRMnk3Z0g3ODJMN2FIUGZrSERQSWFyUkpMdThSXzJzQmtZalBVSFZ4VHlnOV9TQVo3b3pQNnI2Y1BuOEsxcjBpUnpvcWRBZnhYQmFTcXByYkpycGhuUFgyakRlZG1WSjh5ajRCWm1IampEVEhLekV2RzViX0oyQTVDQU1TalkzaDRpRzZmLWRnTm9DV0djTHQybjlvZkEtYnNTcFBNc1B0Nn